174 related articles for article (PubMed ID: 21367805)
21. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.
Shinsako K; Mizuno T; Terada T; Watanabe J; Kamba T; Nakamura E; Ogawa O; Inui K
Int J Clin Oncol; 2010 Oct; 15(5):512-4. PubMed ID: 20340037
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience.
Rey PM; Villavicencio H
Oncology; 2008; 74(3-4):245-6. PubMed ID: 18716419
[TBL] [Abstract][Full Text] [Related]
23. Role of sorafenib in renal cell carcinoma: focus on elderly patients.
Procopio G
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1689-92. PubMed ID: 22050017
[TBL] [Abstract][Full Text] [Related]
24. Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Wood LS; Manchen B
Clin J Oncol Nurs; 2007 Oct; 11(5):649-56. PubMed ID: 17962173
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib for the management of advanced renal cell carcinoma.
Escudier B
Expert Rev Anticancer Ther; 2011 Jun; 11(6):825-36. PubMed ID: 21707277
[TBL] [Abstract][Full Text] [Related]
26. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
Bellmunt J; Fishman M; Eisen T; Quinn D
Expert Rev Anticancer Ther; 2010 Jun; 10(6):825-35. PubMed ID: 20553208
[TBL] [Abstract][Full Text] [Related]
27. Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients.
Ueda T; Imamura Y; Komaru A; Fukasawa S; Sazuka T; Suyama T; Naya Y; Nihei N; Ichikawa T; Maruoka M
Int J Urol; 2010 Sep; 17(9):811-5. PubMed ID: 20649824
[TBL] [Abstract][Full Text] [Related]
28. [Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
Schrader AJ; Hegele A; Olbert P; Buer J; Jeron A; Hofmann R
Urologe A; 2007 Sep; 46(9):1291. PubMed ID: 17668165
[No Abstract] [Full Text] [Related]
29. Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
Ansari J; Fatima A; Chaudhri S; Bhatt RI; Wallace M; James ND
Onkologie; 2009 Feb; 32(1-2):44-6. PubMed ID: 19209019
[TBL] [Abstract][Full Text] [Related]
30. Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.
Kamada P; Dudek AZ
Cancer Invest; 2010 Jun; 28(5):501-4. PubMed ID: 20014944
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis.
Hilger RA; Richly H; Grubert M; Kredtke S; Thyssen D; Eberhardt W; Hense J; Schuler M; Scheulen ME
Int J Clin Pharmacol Ther; 2009 Jan; 47(1):61-4. PubMed ID: 19203541
[No Abstract] [Full Text] [Related]
32. Hand-foot and stump syndrome to sorafenib.
Lai SE; Kuzel T; Lacouture ME
J Clin Oncol; 2007 Jan; 25(3):341-3. PubMed ID: 17235051
[No Abstract] [Full Text] [Related]
33. Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
Hutson TE; Bellmunt J; Porta C; Szczylik C; Staehler M; Nadel A; Anderson S; Bukowski R; Eisen T; Escudier B;
Eur J Cancer; 2010 Sep; 46(13):2432-40. PubMed ID: 20656473
[TBL] [Abstract][Full Text] [Related]
34. One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients.
Kawashima A; Takayama H; Arai Y; Tanigawa G; Nin M; Kajikawa J; Imazu T; Kinoshita T; Yasunaga Y; Inoue H; Nishimura K; Takada S; Nishimura K; Tsujimura A; Nonomura N;
Eur J Cancer; 2011 Jul; 47(10):1521-6. PubMed ID: 21550799
[TBL] [Abstract][Full Text] [Related]
35. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
[TBL] [Abstract][Full Text] [Related]
36. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
37. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Eng FC; Easson AM; Szentgyorgyi E; Knox JJ
Eur J Surg Oncol; 2009 Feb; 35(2):219-21. PubMed ID: 17976949
[No Abstract] [Full Text] [Related]
38. [Nexavar clinical registry].
Büchler T
Klin Onkol; 2010; 23(4):269-70. PubMed ID: 20806826
[No Abstract] [Full Text] [Related]
39. Sorafenib tosylate in advanced kidney cancer: past, present and future.
Porta C; Paglino C; Imarisio I; Ferraris E
Anticancer Drugs; 2009 Jul; 20(6):409-15. PubMed ID: 19436197
[TBL] [Abstract][Full Text] [Related]
40. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
